Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes 57:1461-1462, 2008
DOI: 10.2337/db08-0454
© 2008 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stanger, B. Z.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanger, B. Z.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Commentary

HNF4A and Diabetes

Injury Before Insult?

Ben Z. Stanger

From the Division of Gastroenterology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Corresponding author: Ben Z. Stanger, Division of Gastroenterology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd., Philadelphia, PA 19104. E-mail: bstanger{at}mail.med.upenn.edu

Abbreviations: MODY, maturity-onset diabetes of the young

One of the distinguishing features of vertebrate development is its highly regulative nature. Following developmental perturbations, vertebrate embryos exhibit a robust ability to compensate and normalize structure. However, such appearances may be deceiving, as it has become clear that relatively mild perturbations in embryonic growth can result in profound metabolic disorders—including diabetes—decades later. This association has important clinical implications, but a complete understanding of the cellular and molecular relationship between embryonic development and adult physiology has been slow to emerge.

The first compelling evidence that intrauterine environment dictates later metabolic outcome was the cohort study of Ravelli et al. (1) of 300,000 men conceived during the Dutch famine of 1944–1945. Embryos exposed to malnutrition during the first half of pregnancy, but not later, had significantly higher rates of obesity at age 19 years, indicating that a nutrient-deprived environment early in development has long-lasting metabolic consequences (1). Human and animal studies have subsequently confirmed a relationship between embryonic environment, particularly intrauterine growth retardation, and later occurrence of type 2 diabetes (rev. in 2,3). Although it was initially postulated that hypothalamic-mediated changes in appetite might underlie adult metabolic derangements, low–birth weight infants were found to also have reduced pancreatic β-cell mass (4). This suggests that the increased risk of type 2 diabtes in low–birth weight babies might be due to developmental deficiencies in β-cell mass, leading to inadequate insulin secretion in the face of age-related increases in demand. These and other findings became embodied in the so-called "thrifty phenotype" hypothesis, which postulates that the embryonic environment forecasts the nutritional state that is likely to exist after birth, thereby leading to permanent changes in β-cell mass and insulin responsiveness (5). Such durable changes in β-cells following nutritional deprivation may be mediated, at least in part, by chromatin remodeling (6).

Recently, genetic determinants of type 2 diabetes have taken center stage (7). It is unknown whether these newly identified disease-modifying genes confer increased risk through developmental or functional mechanisms. But a subset of genes, particularly those responsible for maturity-onset diabetes of the young (MODY), have direct roles in both islet development and β-cell physiology. MODY1 is a disorder characterized by defective glucose-stimulated insulin secretion (8) and is caused by mutations in the gene encoding hepatocyte nuclear factor-4{alpha} (HNF4A) (9). HNF4{alpha} directly regulates genes involved in glucose transport and glycolysis (10). Two groups genetically engineered mice to lack HNF4{alpha} in β-cells (HNF4{alpha}loxP/loxP;Ins-Cre) and found that such animals exhibit normal islet architecture but defective glucose-stimulated insulin secretion in β-cells (11,12). Unexpectedly, one of these studies found that HNF4{alpha}loxP/loxP;Ins-Cre mice exhibit hyperinsulinemia, glucose intolerance, and mild hypoglcemia (11). This result was surprising both because of the paradoxical relationship between insulin levels and glucose responsiveness and because MODY1 patients with HNF4A mutations exhibit the opposite phenotype: hypoinsulinemic hyperglycemia.

Based on these findings, Harries et al. (13) examined 108 newborn infants with HNF4A mutations to determine whether they exhibited the same spectrum of metabolic abnormalities as HNF4A mutant mice. Remarkably, a subset of newborns with HNF4A mutations also had hypoglycemia and/or hyperinsulinemia, despite the fact that adults with the same mutations were expected to develop diabetes. Furthermore, some infants also exhibited fetal overgrowth (macrosomia), likely as a result of fetal exposure to high insulin levels (13). In this issue of Diabetes, the same group (14) describes a detailed characterization of human HNF4A transcription and genotype/phenotype correlation. HNF4A is transcribed from two promoters, P1 and P2, that give rise to nine distinct isoforms through differential exon usage at the 5' and 3' ends of the gene. Harries et al. determined that all HNF4A transcripts in the adult liver and kidney are derived from P1, whereas all transcripts in the adult pancreas and small intestine are derived from P2 (other parts of the gut utilize both promoters). In the embryonic pancreas, transcripts from both the P1 and P2 promoters were detected. Therefore, within the pancreas, the P2 promoter is utilized by both embryo and adult, whereas the P1 promoter is exclusively embryonic.

By examining the location of HNF4A mutations in 190 subjects from 58 MODY families, the authors found an interesting trend: individuals with mutations that affect all HNF4A isoforms have an earlier onset of diabetes than those with mutations affecting only P2-derived isoforms or the P2 promoter itself. Based on this statistical finding, the authors propose that mutations that affect only adult transcripts result in milder phenotypes because patients with these mutations are spared the consequence of losing developmentally important P1-derived HNF4{alpha} transcripts. However, there are several alternative explanations for this correlation. Most importantly, the differential effect on protein function of any particular HNF4A mutation could outweigh the effect of disrupting P2-derived transcripts during development. Furthermore, HNF4{alpha} has critical roles during early embryogenesis and liver development (15,16), and, thus, HNF4{alpha} mutations could perturb metabolism through activities in other tissues. Animal models might help resolve some of these questions, although mice with a β-cell–specific deletion of HNF4{alpha} do not develop overt diabetes but instead have defects in β-cell proliferation (17).

Thus, at present, the mechanism by which mutations in HNF4A cause defective insulin secretion remains unresolved. Likewise, it is unknown why some individuals with HNF4A mutations paradoxically develop neonatal hyperinsulinism and macrosomia. Although it is clear that β-cell mass is subject to regulation in adult life (1820), embryonic cell ablation studies point to the coexistence of limits on pancreatic growth that are imprinted during prenatal life (21). This finding, together with the epidemiologic evidence supporting the "thrifty hypothesis," suggests that autonomous growth constraints established during pancreatic development may lie beneath the normal regulative capacity of β-cells. The hypothesis presented by Harries et al. that HNF4A participates in a process of embryonic programming is interesting and warrants further investigation. The next challenge will be to understand how the developmental and physiologic functions of disease-modifying genes conspire to cause diabetes—adding adult insult to an underlying embryonic injury.


    ACKNOWLEDGMENTS
 
The author is indebted to Kenneth Polonsky for helpful suggestions.


    FOOTNOTES
 
See accompanying original article, p. 1745.


    REFERENCES
 TOP
 REFERENCES
 

  1. Ravelli GP, Stein ZA, Susser MW: Obesity in young men after famine exposure in utero and early infancy. N Engl J Med 295:349–353, 1976[Abstract]
  2. Martin-Gronert MS, Ozanne SE: Experimental IUGR and later diabetes. J Intern Med 261:437–452, 2007[Medline]
  3. Simmons R: Developmental origins of adult metabolic disease: concepts and controversies. Trends Endocrinol Metab 16:390–394, 2005[Medline]
  4. Van Assche FA, De Prins F, Aerts L, Verjans M: The endocrine pancreas in small-for-dates infants. Br J Obstet Gynaecol 84:751–753, 1977[Medline]
  5. Hales CN, Barker DJ: The thrifty phenotype hypothesis. Br Med Bull 60:5–20, 2001[Abstract/Free Full Text]
  6. Simmons RA: Developmental origins of beta-cell failure in type 2 diabetes: the role of epigenetic mechanisms. Pediatr Res 61:64R–67R, 2007[Medline]
  7. Frayling TM: Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8:657–662, 2007[Medline]
  8. Byrne MM, Sturis J, Fajans SS, Ortiz FJ, Stoltz A, Stoffel M, Smith MJ, Bell GI, Halter JB, Polonsky KS: Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes 44:699–704, 1995[Abstract]
  9. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 384:458–460, 1996[Medline]
  10. Stoffel M, Duncan SA: The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 94:13209–13214, 1997[Abstract/Free Full Text]
  11. Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, Duncan SA, Kaestner KH: The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest 115:1006–1015, 2005[Medline]
  12. Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, Nammo T, Yoneda K, Inoue Y, Sladek FM, Magnuson MA, Kasai H, Miyagawa J, Gonzalez FJ, Shimomura I: Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. J Biol Chem 281:5246–5257, 2006[Abstract/Free Full Text]
  13. Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT: Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 4:e118, 2007[Medline]
  14. Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, Njølstad PR, Ellard S, Hattersley AT: The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal development. Diabetes 57:1745–1752, 2008[Abstract/Free Full Text]
  15. Li J, Ning G, Duncan SA: Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev 14:464–474, 2000[Abstract/Free Full Text]
  16. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, Kaestner KH, Rossi JM, Zaret KS, Duncan SA: Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 34:292–296, 2003[Medline]
  17. Gupta RK, Gao N, Gorski RK, White P, Hardy OT, Rafiq K, Brestelli JE, Chen G, Stoeckert CJ, Jr, Kaestner KH: Expansion of adult beta-cell mass in response to increased metabolic demand is dependent on HNF-4alpha. Genes Dev 21:756–769, 2007[Abstract/Free Full Text]
  18. Parsons JA, Brelje TC, Sorenson RL: Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 130:1459–1466, 1992[Abstract]
  19. Nir T, Melton DA, Dor Y: Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117:2553–2561, 2007[Medline]
  20. Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M: Regulated β-cell regeneration in the adult mouse pancreas. Diabetes 57:958–966, 2008[Abstract/Free Full Text]
  21. Stanger BZ, Tanaka AJ, Melton DA: Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. Nature 445:886–891, 2007[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article:

The Diabetic Phenotype in HNF4A Mutation Carriers Is Moderated By the Expression of HNF4A Isoforms From the P1 Promoter During Fetal Development
Lorna W. Harries, Jonathan M. Locke, Beverley Shields, Neil A. Hanley, Karen Piper Hanley, Anna Steele, Pål R. Njølstad, Sian Ellard, and Andrew T. Hattersley
Diabetes 2008 57: 1745-1752. [Abstract] [Full Text] [PDF]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stanger, B. Z.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanger, B. Z.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum